Astria Therapeutics (NASDAQ:ATXS) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research note published on Tuesday morning, Benzinga reports. The brokerage currently has a $16.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Astria Therapeutics’ Q3 2024 earnings at ($0.47) EPS, Q4 2024 earnings at ($0.53) EPS, FY2024 earnings at ($1.82) EPS, FY2025 earnings at ($1.80) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($1.99) EPS and FY2028 earnings at ($1.68) EPS.

Other analysts also recently issued reports about the stock. Wedbush reissued an outperform rating and set a $22.00 price target on shares of Astria Therapeutics in a report on Friday, May 10th. Oppenheimer dropped their target price on Astria Therapeutics from $29.00 to $25.00 and set an outperform rating on the stock in a research report on Tuesday, May 21st. Finally, TD Cowen assumed coverage on Astria Therapeutics in a research note on Monday, July 29th. They issued a buy rating and a $35.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of Buy and a consensus price target of $25.20.

Astria Therapeutics Price Performance

Shares of Astria Therapeutics stock opened at $11.07 on Tuesday. Astria Therapeutics has a 1 year low of $4.26 and a 1 year high of $16.90. The stock has a market cap of $607.89 million, a PE ratio of -4.77 and a beta of 0.73. The firm has a fifty day moving average price of $10.12 and a 200 day moving average price of $11.37.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). As a group, equities analysts expect that Astria Therapeutics will post -1.62 EPS for the current year.

Institutional Trading of Astria Therapeutics

Several large investors have recently bought and sold shares of ATXS. Susquehanna Fundamental Investments LLC acquired a new position in shares of Astria Therapeutics during the 2nd quarter worth approximately $400,000. Millennium Management LLC lifted its position in Astria Therapeutics by 13.5% during the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after buying an additional 218,518 shares in the last quarter. Affinity Asset Advisors LLC boosted its stake in Astria Therapeutics by 15.4% during the second quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company’s stock worth $8,878,000 after buying an additional 130,000 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Astria Therapeutics in the 2nd quarter valued at $2,561,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Astria Therapeutics in the 2nd quarter worth $171,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.